Skip to main content

Video+

All video interviews

Louis Aronne

04-06-2022 | ADA 2022 | Conference coverage | Video

SURMOUNT-1: Heralding a ‘golden age’ for obesity treatment

Louis Aronne discusses the results of SURMOUNT-1, and why he believes they may represent the start of a major shift in the treatment of people with obesity.

Sanjay Kalra

11-04-2022 | Type 1 diabetes | View from the clinic | Article

Addressing the challenges of Ramadan for people with diabetes

Sanjay Kalra explains why it is so important for healthcare professionals anywhere in the world to understand about Ramadan and the ramifications for people with diabetes.

Julian Hamilton-Shield

06-04-2022 | Children | View from the clinic | Article

Treatment priorities in children with type 2 diabetes

Julian Hamilton-Shield explains why weight loss is the key to type 2 diabetes management in children (2:04).

Phil Zeitler

05-04-2022 | Children | View from the clinic | Article

Why type 2 diabetes is so challenging to manage in children

Phil Zeitler discusses the pathophysiology of type 2 diabetes in children, and why it is so resistant to conventional management (2:58). 

AG Unnikrishnan

05-04-2022 | Children | View from the clinic | Article

When to screen for type 2 diabetes in children

AG Unnikrishnan highlights the problem of underdiagnosis of type 2 diabetes in children, and explains who to prioritize for screening (2:14).

Adriaan Voors

02-03-2022 | Empagliflozin | Video

EMPULSE: The ‘missing link’ for empagliflozin in heart failure

Adriaan Voors discusses the EMPULSE trial of empagliflozin given just after stabilization of de novo or decompensated chronic heart failure.

Sambit Das

16-12-2021 | Hypoglycemia | Video

What is hypoglycemia-associated autonomic failure?

Sambit Das gives the highlights of his ESICON presentation on the etiology and management of hypoglycemia-associated autonomic failure.

Mikhail Kosiborod

01-11-2021 | Dapagliflozin | Commentary | Video

PRESERVED-HF: Support for dapagliflozin to improve HFpEF health status

Mikhail Kosiborod outlines the findings from the PRESERVED-HF trial, demonstrating that dapagliflozin improves symptoms and physical function in people with heart failure with preserved ejection fraction, and discusses the promise of SGLT2 inhibitors for meeting the treatment goals in this population. 

Mohammad Wali Naseri

28-10-2021 | Sulfonylureas | Conference coverage | Video

SAFES summit 2021: Using modern sulfonylureas

Mohammad Wali Naseri outlines best practice for use of modern sulfonylureas in people with type 2 diabetes, as presented at the 2021 South Asian Federation for Endocrine Societies summit.

Stefano Del Prato

22-10-2021 | Tirzepatide | Video

SURPASS-4: Tirzepatide as an alternative to insulin glargine in type 2 diabetes

Stefano Del Prato discusses the advantages of tirzepatide over insulin glargine for people with type 2 diabetes, and how the SURPASS-4 findings fit with those of the rest of the clinical trial program (7:42).

Parth Narendran

08-10-2021 | EASD 2021 | Conference coverage | Video

The ADA/EASD type 1 diabetes consensus: Comprehensive and up to date

Parth Narendran gives his highlights of the ADA/EASD type 1 diabetes management consensus report, and explains how it can support clinicians to deliver improved services for their patients.

Pinar Topsever

01-10-2021 | EASD 2021 | Conference coverage | Video

How will the TriMaster results impact patient-centered care?

Pinar Topsever comments on the TriMaster study of a stratified medicine approach to second- and third-line treatment for type 2 diabetes, and discusses what the results mean for primary care practice.

Anne Peters

01-10-2021 | EASD 2021 | Conference coverage | Video

Management of type 1 diabetes: ADA/EASD consensus report

Anne Peters talks about the goals of the ADA/EASD type 1 diabetes management consensus report, the issues to urgently address, and the joys of being part of a trans-Atlantic collaboration.

Stephanie Amiel

01-10-2021 | EASD 2021 | Conference coverage | Video

The HARPdoc intervention for people with poor hypoglycemia awareness

Stephanie Amiel discusses the outcomes of the HARPdoc randomized trial and explains why the intervention could be so powerful for people with type 1 diabetes and reduced hypoglycemia awareness.

Andrew Hattersley

29-09-2021 | EASD 2021 | Conference coverage | Video

The TriMaster study of individualized medicine in type 2 diabetes

Andrew Hattersley outlines the findings from TriMaster, a randomized crossover trial demonstrating the potential of an individualized treatment approach for people with type 2 diabetes who require treatment intensification after first-line metformin. 

David Wheeler

15-09-2021 | ESC 2021 | Conference coverage | Video

FIGARO: Where will finerenone fit into diabetic kidney disease treatment?

David Wheeler talks about the findings of the FIGARO trial, the use of finerenone in people with type 2 diabetes, and how this may fit with SGLT2 inhibitors.

Stefan Anker

29-08-2021 | ESC 2021 | Conference coverage | Video

EMPEROR-Preserved: Diabetes medication becomes first effective HFpEF therapy

EMPEROR-Preserved investigator Stefan Anker discusses the role of SGLT2 inhibitors in patients with heart failure.

Kevin Fernando

29-08-2021 | ESC 2021 | Conference coverage | Video

EMPEROR-Preserved: The implications for primary care

Kevin Fernando discusses the EMPEROR-Preserved findings and their likely impact on the treatment of people with heart failure with preserved ejection fraction, with or without diabetes, in primary care.

Katharine Barnard-Kelly

09-07-2021 | Mental health | Video | Article

An international Collaborative Community to address suicide risk in diabetes

Katharine Barnard-Kelly explains how the international RESCUE Collaborative Community, in partnership with the US FDA, aims to raise awareness of the risk for suicide in people with diabetes (2:25)

Patrick Holmes

29-06-2021 | ADA 2021 | Conference coverage | Video

What do the GRADE results mean for clinical practice?

Patrick Holmes discusses whether the GRADE study answers the question of which type 2 diabetes medication should be used after metformin, and comments on the generalizability of the findings.